返回 Agenda
Session 2: Lessons Learned and Best Practices for Decentralized Clinical Trials: Can We Plan and Execute More Patient-Friendly Clinical Trials?
Session Chair(s)
Megan Doyle, JD, MPH
Associate Vice President, Assistant General Counsel - Diagnostics
Eli Lilly & Company, United States
This session will focus on what we’ve learned thus far in trying to implement decentralized techniques in clinical trials. Specifically, speakers will share lessons learned and best practices observed to date. Additionally, based on these lessons learned, we will discuss remaining challenges and paths forward for addressing those challenges.
Learning Objective : At the conclusion of this session, participants should be able to:- Articulate best practices in planning and executing decentralized trials
- Understand some lessons learned related to using decentralized techniques in clinical trials to date
- Assess the challenges that remain for broad scale decentralized trial adoption
Speaker(s)
Speakers
Scott Askin, MSc
Novartis Pharma AG, Switzerland
Global Program Regulatory Director
Speaker
Abba Elizabeth Theogaraj, PhD
Roche, Switzerland
Regulatory Senior Group Director
Speaker
Reem Yunis, PhD
Medable, United States
Vice President, Digital Transformation Strategy
Speaker
Sarah Krug, MS
CANCER101, United States
Executive Director